Product Description
Nintedanib is an approved treatment for IPF, which reduces the rate of decline in forced vital capacity (FVC). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33902584/)
Mechanisms of Action: Apoptosis Inhibitor,VEGF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis
Known Adverse Events: Hypertension | Abdominal Pain | Headache | Pain Unspecified | Diarrhea
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Thailand, Ukraine, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Bronchiolitis|COVID-19|Lung Diseases, Interstitial|Lymphangioleiomyomatosis|Pneumonia|Pulmonary Fibrosis|Scleroderma, General
Phase 2: Anthracosis|Asbestosis|Breast Cancer|Lung Cancer|Mesothelioma|Pneumoconiosis|Radiation Pneumonitis|Silicosis|Telangiectasia, Hereditary Hemorrhagic
Phase 1: Acute Myeloid Leukemia|Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Progressive Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| InPedILDâ¢-ON | P3 |
Active, not recruiting |
Lung Diseases, Interstitial |
2025-12-06 |
|
| NU 17H04 | P1 |
Active, not recruiting |
Acute Myeloid Leukemia |
2025-12-01 |
|
| 1199-0378 | P3 |
Unknown Status |
Lung Diseases, Interstitial |
2025-08-11 |
|
| InPedILD®-ON | P3 |
Active, not recruiting |
Lung Diseases, Interstitial |
2025-07-14 |